Miltefosine Administration in Cats with Refractory Sporotrichosis

Francina dos Santos Silva, Simone Carvalho dos Santos Cunha, Andrea Regina de Souza Baptista, Vivian dos Santos Baptista, Kássia Valéria Gomes Coelho da Silva, Thais Fernanda Queiroz Coêlho, Ana Maria Reis Ferreira

Abstract


Background: Sporotrichosis is a zoonosis caused by fungi of the Sporothrix schenckii complex. Cats have important zoonotic potential due to the high parasite load found in the cutaneous lesions. Refractory cases to antifungal therapy are increasing, becoming a public health problem. Miltefosine is a drug with high in vitro activity against Sporothrix brasiliensis. However, this efficacy has not been confirmed in vivo yet and administration has not been studied in the feline species. This study aimed to evaluate the effectiveness and safety of miltefosine administration in cats with resistant sporotrichosis.

Materials, Methods & Results: Ten cats with refractory sporotrichosis were included in this study. Inclusion criteria were previous diagnosis for sporotrichosis associated with therapy with oral antifungals (itraconazole and/or potassium iodide) for more than one year, followed by one of these conditions: incomplete clinical remission, worsening of disease during treatment or recurrence after conventional treatment. Cats underwent clinical and dermatological examinations. Data on lifestyle and previous treatments were provided by the owners. Fungal culture and histochemical techniques were performed in all cats before miltefosine treatment. Blood samples were collected before and during the study for laboratory tests, such as blood count, blood urea nitrogen (BUN), serum creatinine, alanine aminotransferase (ALT) and alkaline phosphatase, as well as serology for Feline Immunodeficiency (FIV) and Feline Leukemia (FeLV). Miltefosine was prescribed at a dosage of 2 mg/kg orally every 24 h. The animals were monitored by phone during the whole process and reassessed on days 0, 15, 30 and 45 of the treatment. Out of 10 cats, lesions were present on the nose in nine, ears in four, periocular areas in one and limbs in four. One cat received treatment for 45 days, six for 30 days, one for 21 days, one for 15 days and one for 3 days. One cat showed no response to the treatment and nine showed disease progression. Hyporexia and weight loss were the most frequent clinical signs related to miltefosine treatment, followed by sialorrhea, vomiting and diarrhea. Few adverse effects on hematology and biochemistry (mainly renal and hepatic parameters) were observed during the study. Hematocrit decrease was observed in four animals. However, only one cat had hematocrit decrease below normal values (anemia), which was already present before miltefosine administration. Other cats had a decrease of five points. Three cats showed elevation in leucometria and four in plasma protein. In relation to renal and hepatic biochemistry, one animal showed a BUN increase and another one showed a transient increase in ALT. Two animals started the treatment with increased ALT but had no problems during the study and values decreased even during the miltefosine administration.

Discussion: Although two cats showed sialorrhea, most owners did not report difficulty in administering the drug orally, representing an advantage of this medication. Weight loss, secondary to gastrointestinal changes, was the most clinically relevant alteration. The most frequent hematological alteration was hematocrit decrease and only the animal that started the study with 20% hematocrit ended the study with anemia. Renal and hepatic parameters were not significant in the cats of this study. Miltefosine did not lead to sporotrichosis remission in this small population of cats, which reveals that, despite its in vitro efficacy against Sporothrix spp., the drug is not effective in vivo in the feline species. Further studies are needed to investigate the efficacy of this drug in a larger number of cats, and possible reasons for its in vivo ineffectiveness.


Full Text:

PDF

References


Almeida-Paes R., Oliveira M.M., Freitas D.F., Valle A.C., Gutierrez-Galhardo M.C. & Zancopé-Oliveira R.M. 2016. Refractory sporotrichosis due to Sporothrix brasiliensis in humans appears to be unrelated to in vivo resistance. Medical Mycology. [In press].

Andrade H.M., Toledo V.P., Pinheiro M.B., Guimarães T.M., Oliveira N.C., Castro J.A., Silva R.N., Amorim A.C., Brandão R.M., Yoko M., Silva A.S., Dumont K., Ribeiro Jr. M.L., Bartchewsky W. & Monte S.J. 2011. Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil. Veterinary Parasitology. 181(2-4): 83-90.

Arrillaga-Moncrieff I., Capilla J., Mayayo E., Marimon R., Mariné M., Gené J., Cano J. & Guarro J. 2009. Different virulence levels of the species of Sporothrix in a murine model. Clinical Microbiology and Infection. 15(7): 651-655.

Borba-Santos L.P., Gagini T., Ishida K., Souza W. & Rozental S. 2015. Miltefosine is active against Sporothrix brasiliensis isolates with in vitro low susceptibility to amphotericin B or itraconazole. Journal of Medical Microbiology. 64: 415-422.

Brilhante R.S.N., Malaquias A.D.M., Caetano E.P., Castelo-Branco D.S., Lima R.A., Marques F.J., Silva N.F., Alencar L.P., Monteiro A.J., Camargo Z.P., Bandeira T.J., Rodrigues A.M., Cordeiro R.A., Moreira J.L., Sidrim J.J. & Rocha M.F. 2014. In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp. Medical Mycology. 52: 320-325.

De Beer Z.W., Duong T.A. & Wingfield M.J. 2016. The divorce of Sporothrix and Ophiostoma: solution to a problematic. Studies in Mycology. 83: 165-191.

Greene C.E. 2006. Antifungal chemotherapy. In: Greene C.E. (Eds). Infectious diseases of the dog and the cat. Philadelphia: Saunders Elsevier, pp.542-550.

Gremião I.D.F., Miranda L.H.M., Reis E.G., Rodrigues A.M. & Pereira S.A. 2017. Zoonotic epidemic of sporotrichosis: Cat to human transmission. PLOS Pathogens. 13(1): 1-7.

Gremião I.D.F., Pereira S.A., Rodrigues A.M., Figueiredo F.B., Nascimento Jr. A., Santos I.B. & Schubach T.M.P. 2006. Tratamento cirúrgico associado à terapia antifúngica convencional na esporotricose felina. Acta Scientiae Veterinariae. 34(2): 221-223.

Gremião I.D.F, Schubach T.M.P, Pereira S.A., Rodrigues A.M., Honse C.O. & Barros M.B.L. 2011. Treatment of refractory feline sporotrichosis with a combination of intralesional amphotericin B and oral itraconazole. Australian Veterinary Journal. 89(9): 346-351.

Mateo M., Maynard L., Vischer L., Bianciardi P. & Miró G. 2009. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitololy Research. 105: 155-162.

Miró G., Oliva G., Cruz I., Cañavate C., Mortarino M., Vischer C. & Bianciardi P. 2009. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Veterinary Dermatology. 20: 397-404.

Montenegro H., Rodrigues A.M., Dias M.A., Silva E.A., Bernardi F. & Carmargo Z.P. 2014. Feline sporotrichosis due to Sporothrix brasiliensis: an emerging animal infection in São Paulo, Brazil. BMC Veterinary Research. 10: 269.

Pereira S.A., Menezes R.C., Gremião I.D.F., Silva J.N., Honse C.O., Figueiredo F.B., da Silva D.T., Kitada A.A., dos Reis E.G. & Schubach T.M.P. 2011. Sensitivity of cytopathological examination in the diagnosis of feline sporotrichosis. Journal of Feline Medicine and Surgery. 13: 220-223.

Pereira S.A., Schubach T.M.P., Gremião I.D.F., Silva D.T., Figueiredo F.B., Assis N.V. & Passos S.R.L. 2009. Aspectos terapêuticos da esporotricose felina. Acta Scientiae Veterinariae. 37: 311-321.

Reis E.G., Gremião I.D.F., Kitada A.A., Rocha R.F., Castro V.S., Barros M.B., Menezes R.C., Pereira S.A. & Schubach T.M.P. 2012. Potassium iodide capsule in the treatment of feline sporotrichosis. Journal of Feline Medicine and Surgery. 14: 399-404.

Rodrigues A.M., De Hoog G.S. & Camargo Z.P. 2016. Sporothrix Species Causing Outbreaks in Animals and Humans Driven by Animal–Animal Transmission. PLOS Pathogens. 12(7): 1-7.

Schubach T. M. P., Menezes R. C. & Wanke B. 2012. Sporotrichosis. In: Greene C.E. (Eds). Infectious Diseases of the dog and cat. 4th edn. St Louis: Elsevier, pp.645-650.

Schubach T.M., Schubach A., Okamoto T., Barros M.B., Figueiredo F.B., Cuzzi T., Fialho-Monteiro P.C., Reis R.S., Perez M.A. & Wanke B. 2004. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). Journal of American Veterinary Medical Association. 224: 1623-1629.

Silva J.N., Passos S.R.L., Menezes R.C., Gremião I.D.F., Schubach T.M.P., Oliveira J.C., Figueiredo A.B.F. & Pereira S.A. 2015. Diagnostic accuracy assessment of cytopathological examination of feline sporotrichosis. Medical Mycology. 53(8): 880-884.

Sindermann H &Engel J. 2006. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 100 (Suppl 1): 17-20.

Souza C.P., Lucas R., Ramadinha R. & Pires T.B. 2016. Cryosurgery in association with itraconazole for the treatment of feline sporotrichosis. Journal of Feline Medicine and Surgery. 18(2): 137-143.

Woerly V., Maynard L., Sanquer A. & Eun H.M. 2009. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitology Research. 105(2): 463-469.




DOI: https://doi.org/10.22456/1679-9216.83639

Copyright (c) 2018 Francina dos Santos Silva, Simone Carvalho dos Santos Cunha, Andrea Regina de Souza Baptista, Vivian dos Santos Baptista, Kássia Valéria Gomes Coelho da Silva, Thais Fernanda Queiroz Coêlho, Ana Maria Reis Ferreira

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.